{"id":538891,"date":"2026-07-02T10:15:24","date_gmt":"2026-07-02T10:15:24","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/538891\/staphylococcus-aureus-bacteremia-sab-market-is-projected-to-boom-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight.html"},"modified":"2026-07-02T10:15:24","modified_gmt":"2026-07-02T10:15:24","slug":"staphylococcus-aureus-bacteremia-sab-market-is-projected-to-boom-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight","status":"publish","type":"post","link":"http:\/\/www.northcarolinaheadlines.com\/news\/story\/538891\/staphylococcus-aureus-bacteremia-sab-market-is-projected-to-boom-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight.html","title":{"rendered":"Staphylococcus aureus Bacteremia (SAB) Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/07\/1782921461.jpg\" style=\"border:none !important\" target=\"_blank\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-medium wp-image-29\" title=\"Staphylococcus aureus Bacteremia (SAB) Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/07\/1782921461.jpg\" alt=\"Staphylococcus aureus Bacteremia (SAB) Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The market dynamics for Staphylococcus aureus Bacteremia (SAB) is witnessing steady growth driven by the increasing incidence of bloodstream infections, rising prevalence of methicillin-resistant Staphylococcus aureus (MRSA), growing adoption of rapid diagnostic technologies, and advancements in targeted anti-infective therapies. Additionally, the launch of emerging therapies such as AP-SA02 (Armata Pharmaceuticals), XF-73 (Destiny Pharma\/EMV Capital), and others will further fuel the market.<\/div>\n<p style=\"text-align: justify\">DelveInsight, a leading market research firm, announces the release of its latest report, &#8220;DelveInsight&#8217;s Staphylococcus aureus Bacteremia (SAB) Market Insights, Epidemiology, and Market Forecast &ndash; 2036.&#8221; This comprehensive report provides an in-depth understanding of Staphylococcus aureus Bacteremia (SAB), including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\">Key Takeaways from the Staphylococcus aureus Bacteremia (SAB) Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The market size for Staphylococcus aureus Bacteremia (SAB) in the leading markets is expected to grow significantly by 2036.<\/p>\n<\/li>\n<li>\n<p>The United States accounted for the highest Staphylococcus aureus Bacteremia (SAB) treatment market size in the 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&#8217;s analysis, the Staphylococcus aureus Bacteremia (SAB) market in the 7MM is expected to increase from approximately USD 1.5 billion in 2022 to nearly USD 4.3 billion by 2036, driven by the launch of emerging therapies and increasing disease burden.<\/p>\n<\/li>\n<li>\n<p>As per secondary research, Staphylococcus aureus is one of the leading causes of nosocomial bacteremia, hospital-acquired pneumonia, and surgical site infections. According to the SENTRY Antimicrobial Surveillance Program, S. aureus accounted for 26.0% of nosocomial bacteremia cases in the United States and 19.5% of infections in Europe.<\/p>\n<\/li>\n<li>\n<p>The incidence of Staphylococcus aureus Bacteremia is estimated to range from 20 to 50 cases per 100,000 population annually, with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia continuing to increase across the United States and Europe.<\/p>\n<\/li>\n<li>\n<p>A US-based study evaluating adult patients with Staphylococcus aureus bacteremia found that approximately 58.7% of infections were healthcare-associated, 23.5% were nosocomial, and 17.8% were community-acquired, highlighting the substantial burden of healthcare-associated infections.<\/p>\n<\/li>\n<li>\n<p>According to the Japan Nosocomial Infections Surveillance program, the proportion of MRSA among all Staphylococcus aureus isolates declined from 60.0% in 2008 to 45.6% in 2022, reflecting improvements in infection control while emphasizing the continued burden of antimicrobial resistance.<\/p>\n<\/li>\n<li>\n<p>Leading Staphylococcus aureus Bacteremia companies, such as Armata Pharmaceuticals, Destiny Pharma\/EMV Capital, Basilea Pharmaceutica, and others, are developing innovative therapies expected to transform the treatment landscape during the forecast period.<\/p>\n<\/li>\n<li>\n<p>The promising Staphylococcus aureus Bacteremia therapies in clinical development include AP-SA02, XF-73, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Keen to know more about the market? Request our sample page at <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/staphylococcus-aureus-bacteremia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/sample-request\/staphylococcus-aureus-bacteremia-market<\/a><\/p>\n<p style=\"text-align: justify\">Key Factors Driving the Staphylococcus aureus Bacteremia (SAB) Market<\/p>\n<p style=\"text-align: justify\">Rising Burden of Antibiotic-resistant Infections: The growing prevalence of MRSA, vancomycin-resistant strains, and other multidrug-resistant pathogens continues to increase the clinical and economic burden of SAB, driving demand for novel antimicrobial therapies capable of overcoming resistance.<\/p>\n<p style=\"text-align: justify\">Increasing Adoption of Rapid Diagnostic Technologies: Advanced molecular diagnostics, including PCR-based assays and MALDI-TOF mass spectrometry, enable rapid identification of Staphylococcus aureus and its resistance profile, facilitating earlier targeted therapy and improving patient outcomes.<\/p>\n<p style=\"text-align: justify\">Advancement of Novel Anti-infective Therapies: The development of bacteriophage therapies, next-generation antibiotics, and biologics is expected to reshape the treatment landscape by improving bacterial clearance while addressing the growing challenge of antimicrobial resistance.<\/p>\n<p style=\"text-align: justify\">Staphylococcus aureus Bacteremia (SAB) Competitive Landscape<\/p>\n<p style=\"text-align: justify\">Several Staphylococcus aureus Bacteremia therapies are currently under clinical development, including AP-SA02 (Armata Pharmaceuticals) and XF-73 (Destiny Pharma\/EMV Capital).<\/p>\n<p style=\"text-align: justify\">These investigational therapies utilize differentiated mechanisms of action, including bacteriophage-based therapy and novel antimicrobial platforms targeting Staphylococcus aureus, including methicillin-resistant strains. These innovative approaches have the potential to improve bacterial eradication, reduce antibiotic resistance, and enhance clinical outcomes in patients with complicated bloodstream infections.<\/p>\n<p style=\"text-align: justify\">Discover more about therapies set to grab major Staphylococcus aureus Bacteremia market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/staphylococcus-aureus-bacteremia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">Staphylococcus aureus Bacteremia Treatment Landscape<\/a><\/p>\n<p style=\"text-align: justify\">Recent Developments in the Staphylococcus aureus Bacteremia (SAB) Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>In January 2026, Armata Pharmaceuticals announced that the US FDA supported advancing AP-SA02 into a Phase III superiority study for complicated Staphylococcus aureus bacteremia following a successful End-of-Phase II meeting.<\/p>\n<\/li>\n<li>\n<p>In January 2026, Armata Pharmaceuticals confirmed that the Phase III trial of AP-SA02 is expected to begin during the second half of 2026, with the FDA also indicating openness toward Qualified Infectious Disease Product (QIDP) designation.<\/p>\n<\/li>\n<li>\n<p>In September 2025, EMV Capital announced that its subsidiary Moirai Acquisitions Limited acquired key assets related to the XF-73 platform from Destiny Pharma to accelerate development of innovative antimicrobial therapies targeting resistant Staphylococcus aureus infections.<\/p>\n<\/li>\n<li>\n<p>In April 2024, the US FDA approved ZEVTERA (ceftobiprole medocaril) for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP) in adults and certain pediatric patients.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">What is Staphylococcus aureus Bacteremia (SAB)?<\/p>\n<p style=\"text-align: justify\">Staphylococcus aureus Bacteremia (SAB) is a serious bloodstream infection caused by the Gram-positive bacterium Staphylococcus aureus. The condition can originate from community-acquired or healthcare-associated infections and is associated with high morbidity and mortality due to complications such as infective endocarditis, metastatic infections, sepsis, osteomyelitis, and pneumonia. Diagnosis relies primarily on blood culture testing and antimicrobial susceptibility analysis, while treatment is guided by methicillin susceptibility using beta-lactam antibiotics for methicillin-sensitive Staphylococcus aureus (MSSA) and agents such as vancomycin or daptomycin for MRSA. Emerging bacteriophage therapies and next-generation antibiotics are expected to significantly improve treatment outcomes for patients with complicated SAB.<\/p>\n<p style=\"text-align: justify\">Staphylococcus aureus Bacteremia (SAB) Epidemiology Segmentation<\/p>\n<p style=\"text-align: justify\">The Staphylococcus aureus Bacteremia (SAB) epidemiology section provides insights into the historical and current Staphylococcus aureus Bacteremia patient pool and forecasted trends for the leading markets. The Staphylococcus aureus Bacteremia market report proffers epidemiological analysis for the study period 2022&ndash;2036 in the leading markets, segmented into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Incident Cases of Staphylococcus aureus Bacteremia (SAB)<\/p>\n<\/li>\n<li>\n<p>Type-specific Incident Cases of Staphylococcus aureus Bacteremia (SAB)<\/p>\n<\/li>\n<li>\n<p>Antibiotic-resistant Incident Cases of Staphylococcus aureus Bacteremia (SAB)<\/p>\n<\/li>\n<li>\n<p>Gender-specific Incident Cases of Staphylococcus aureus Bacteremia (SAB)<\/p>\n<\/li>\n<li>\n<p>Age-specific Incident Cases of Staphylococcus aureus Bacteremia (SAB)<\/p>\n<\/li>\n<li>\n<p>Treatable Cases of Staphylococcus aureus Bacteremia (SAB)<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Scope of the Staphylococcus aureus Bacteremia (SAB) Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Therapeutic Assessment: Staphylococcus aureus Bacteremia current marketed and emerging therapies<\/p>\n<\/li>\n<li>\n<p>Staphylococcus aureus Bacteremia Market Dynamics: Key Market Forecast Assumptions of Emerging Staphylococcus aureus Bacteremia Therapies and Market Outlook<\/p>\n<\/li>\n<li>\n<p>Key Companies: Armata Pharmaceuticals, Destiny Pharma\/EMV Capital, Basilea Pharmaceutica, and others<\/p>\n<\/li>\n<li>\n<p>Key Therapies: AP-SA02, XF-73, ZEVTERA (ceftobiprole medocaril), Vancomycin, Daptomycin, Cefazolin, Oxacillin, Nafcillin, Linezolid, and others<\/p>\n<\/li>\n<li>\n<p>Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies<\/p>\n<\/li>\n<li>\n<p>Unmet Needs, KOL&#8217;s Views, Analyst&#8217;s Views, Staphylococcus aureus Bacteremia Market Access and Reimbursement<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">To know more about Staphylococcus aureus Bacteremia companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/staphylococcus-aureus-bacteremia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">Staphylococcus aureus Bacteremia Clinical Trials and Therapeutic Assessment<\/a><\/p>\n<p style=\"text-align: justify\">Table of Contents<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Staphylococcus aureus Bacteremia Market Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary for Staphylococcus aureus Bacteremia<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Staphylococcus aureus Bacteremia Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Market Share (%) Distribution of Staphylococcus aureus Bacteremia by Therapies<\/p>\n<\/li>\n<li>\n<p>Methodology<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview<\/p>\n<\/li>\n<li>\n<p>Classification<\/p>\n<\/li>\n<li>\n<p>Causes<\/p>\n<\/li>\n<li>\n<p>Signs and Symptoms<\/p>\n<\/li>\n<li>\n<p>Pathophysiology<\/p>\n<\/li>\n<li>\n<p>Clinical Features<\/p>\n<\/li>\n<li>\n<p>Diagnosis<\/p>\n<\/li>\n<li>\n<p>Diagnostic Guidelines<\/p>\n<\/li>\n<li>\n<p>Diagnostic Algorithm<\/p>\n<\/li>\n<li>\n<p>Treatment and Management<\/p>\n<\/li>\n<li>\n<p>Treatment Guidelines and Recommendations<\/p>\n<\/li>\n<li>\n<p>Staphylococcus aureus Bacteremia Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Country-Specific Patient Population of Staphylococcus aureus Bacteremia<\/p>\n<\/li>\n<li>\n<p>Patient Journey<\/p>\n<\/li>\n<li>\n<p>Marketed Therapies<\/p>\n<\/li>\n<li>\n<p>ZEVTERA (ceftobiprole medocaril): Basilea Pharmaceutica<\/p>\n<\/li>\n<li>\n<p>Emerging Drugs<\/p>\n<\/li>\n<li>\n<p>AP-SA02: Armata Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>XF-73: Destiny Pharma\/EMV Capital<\/p>\n<\/li>\n<li>\n<p>Staphylococcus aureus Bacteremia Market Analysis<\/p>\n<\/li>\n<li>\n<p>Market Outlook<\/p>\n<\/li>\n<li>\n<p>Attribute Analysis<\/p>\n<\/li>\n<li>\n<p>Pricing Trends<\/p>\n<\/li>\n<li>\n<p>Launch Year and Therapy Uptake<\/p>\n<\/li>\n<li>\n<p>Country-Wise Staphylococcus aureus Bacteremia Market Analysis (2022&ndash;2036)<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement<\/p>\n<\/li>\n<li>\n<p>KOL Views<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis<\/p>\n<\/li>\n<li>\n<p>Staphylococcus aureus Bacteremia Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Staphylococcus aureus Bacteremia Appendix<\/p>\n<\/li>\n<li>\n<p>Staphylococcus aureus Bacteremia Report Methodology<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">About DelveInsight<\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=staphylococcus-aureus-bacteremia-sab-market-is-projected-to-boom-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=staphylococcus-aureus-bacteremia-sab-market-is-projected-to-boom-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The market dynamics for Staphylococcus aureus Bacteremia (SAB) is witnessing steady growth driven by the increasing incidence of bloodstream infections, rising prevalence of methicillin-resistant Staphylococcus aureus (MRSA), growing adoption of<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/538891"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=538891"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/538891\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=538891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=538891"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=538891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}